logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

mTNBC: capivasertib+paclitaxel shows promise in phase 2 PAKT Trial

The best results were among patient subgroups with PIK3CA/AKT1/PTEN-altered tumors.